A Return Of The Blockbuster, But Can 2009 Launches Live Up To Potential?
Executive Summary
The blockbuster drug tried to claw its way back from the brink in 2009, as drug makers launched several novel drugs and biologics in multi-billion dollar therapeutic categories. While several new drugs offer blockbuster potential, they raise two questions: will they live up to their promise, and if so, how long will it take
You may also be interested in...
2012 Drug Launches Suggest Reasons For Optimism
Launches in 2012 clearly reflect the changes in pharma’s R&D investment priorities in recent years, as the industry has shifted emphasis from primary-care blockbusters to more targeted specialty models. The group includes potential blockbusters like Xeljanz, a dozen novel oncologics, the first new obesity drug in over a decade, and several treatments for rare diseases.
For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few
The outlook for novel drug and biologic approvals in 2010 is strikingly similar to the beginning of 2009: specialty markets continue to gain ground on new products for primary care, and specialty firms continue to gain in the ranks of sponsors while big pharma struggles to put up successful new candidates
For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few
The outlook for novel drug and biologic approvals in 2010 is strikingly similar to the beginning of 2009: specialty markets continue to gain ground on new products for primary care, and specialty firms continue to gain in the ranks of sponsors while big pharma struggles to put up successful new candidates